Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120


Etoricoxib versus indometacin in the treatment of Chinese patients with acute gouty arthritis: a randomized double-blind trial.

Li T, Chen SL, Dai Q, Han XH, Li ZG, Wu DH, Zhang X, Gu JR, Yang NP, Sun LY, Zhang MJ, Li XF, Bao CD.

Chin Med J (Engl). 2013;126(10):1867-71.


Randomised double blind trial of etoricoxib and indometacin in treatment of acute gouty arthritis.

Schumacher HR Jr, Boice JA, Daikh DI, Mukhopadhyay S, Malmstrom K, Ng J, Tate GA, Molina J.

BMJ. 2002 Jun 22;324(7352):1488-92.


Efficacy and safety profile of treatment with etoricoxib 120 mg once daily compared with indomethacin 50 mg three times daily in acute gout: a randomized controlled trial.

Rubin BR, Burton R, Navarra S, Antigua J, LondoƱo J, Pryhuber KG, Lund M, Chen E, Najarian DK, Petruschke RA, Ozturk ZE, Geba GP.

Arthritis Rheum. 2004 Feb;50(2):598-606.


Gastrointestinal tolerability of etoricoxib in rheumatoid arthritis patients: results of the etoricoxib vs diclofenac sodium gastrointestinal tolerability and effectiveness trial (EDGE-II).

Krueger K, Lino L, Dore R, Radominski S, Zhang Y, Kaur A, Simpson R, Curtis S.

Ann Rheum Dis. 2008 Mar;67(3):315-22. Epub 2007 Oct 27. Erratum in: Ann Rheum Dis.2008 May;67(5):732.


Association of baseline disease and patient characteristics with response to etoricoxib and indomethacin for acute gout.

Navarra S, Rubin BR, Yu Q, Smugar SS, Tershakovec AM.

Curr Med Res Opin. 2007 Jul;23(7):1685-91.


Evaluation of the comparative efficacy of etoricoxib and ibuprofen for treatment of patients with osteoarthritis: A randomized, double-blind, placebo-controlled trial.

Wiesenhutter CW, Boice JA, Ko A, Sheldon EA, Murphy FT, Wittmer BA, Aversano ML, Reicin AS; Protocol 071 Study Group.

Mayo Clin Proc. 2005 Apr;80(4):470-9.


A randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis.

Matsumoto AK, Melian A, Mandel DR, McIlwain HH, Borenstein D, Zhao PL, Lines CR, Gertz BJ, Curtis S; Etoricoxib Rheumatoid Arthritis Study Group.

J Rheumatol. 2002 Aug;29(8):1623-30.


The gastrointestinal safety of the COX-2 selective inhibitor etoricoxib assessed by both endoscopy and analysis of upper gastrointestinal events.

Hunt RH, Harper S, Watson DJ, Yu C, Quan H, Lee M, Evans JK, Oxenius B.

Am J Gastroenterol. 2003 Aug;98(8):1725-33.


Efficacy of etoricoxib 60 mg/day and diclofenac 150 mg/day in reduction of pain and disability in patients with chronic low back pain: results of a 4-week, multinational, randomized, double-blind study.

Zerbini C, Ozturk ZE, Grifka J, Maini M, Nilganuwong S, Morales R, Hupli M, Shivaprakash M, Giezek H; Etoricoxib CLBP Study Group.

Curr Med Res Opin. 2005 Dec;21(12):2037-49.


Evaluation of the efficacy of etoricoxib in ankylosing spondylitis: results of a fifty-two-week, randomized, controlled study.

van der Heijde D, Baraf HS, Ramos-Remus C, Calin A, Weaver AL, Schiff M, James M, Markind JE, Reicin AS, Melian A, Dougados M.

Arthritis Rheum. 2005 Apr;52(4):1205-15.


Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor.

Patrignani P, Capone ML, Tacconelli S.

Expert Opin Pharmacother. 2003 Feb;4(2):265-84. Review.


Renal effects of etoricoxib and comparator nonsteroidal anti-inflammatory drugs in controlled clinical trials.

Curtis SP, Ng J, Yu Q, Shingo S, Bergman G, McCormick CL, Reicin AS.

Clin Ther. 2004 Jan;26(1):70-83.


Evaluation of the efficacy and safety of etoricoxib compared with naproxen in two, 138-week randomised studies of patients with osteoarthritis.

Reginster JY, Malmstrom K, Mehta A, Bergman G, Ko AT, Curtis SP, Reicin AS.

Ann Rheum Dis. 2007 Jul;66(7):945-51. Epub 2006 Dec 1.


Etoricoxib in the treatment of osteoarthritis over 52-weeks: a double-blind, active-comparator controlled trial [NCT00242489].

Curtis SP, Bockow B, Fisher C, Olaleye J, Compton A, Ko AT, Reicin AS.

BMC Musculoskelet Disord. 2005 Dec 1;6:58.


A multinational randomized, controlled, clinical trial of etoricoxib in the treatment of rheumatoid arthritis [ISRCTN25142273].

Collantes E, Curtis SP, Lee KW, Casas N, McCarthy T, Melian A, Zhao PL, Rodgers DB, McCormick CL, Lee M, Lines CR, Gertz BJ; Etoricoxib Rheumatoid Arthritis Study Group.

BMC Fam Pract. 2002 May 22;3:10.


Results of a randomized, dose-ranging trial of etoricoxib in patients with osteoarthritis.

Gottesdiener K, Schnitzer T, Fisher C, Bockow B, Markenson J, Ko A, DeTora L, Curtis S, Geissler L, Gertz BJ; Protocol 007 Study Group.

Rheumatology (Oxford). 2002 Sep;41(9):1052-61. Erratum in: Rheumatology (Oxford). 2003 Jun;42(6):814.


Rilonacept in the treatment of acute gouty arthritis: a randomized, controlled clinical trial using indomethacin as the active comparator.

Terkeltaub RA, Schumacher HR, Carter JD, Baraf HS, Evans RR, Wang J, King-Davis S, Weinstein SP.

Arthritis Res Ther. 2013 Feb 1;15(1):R25. doi: 10.1186/ar4159.


Efficacy and tolerability profile of etoricoxib in patients with osteoarthritis: A randomized, double-blind, placebo and active-comparator controlled 12-week efficacy trial.

Leung AT, Malmstrom K, Gallacher AE, Sarembock B, Poor G, Beaulieu A, Castro R, Sanchez M, Detora LM, Ng J.

Curr Med Res Opin. 2002;18(2):49-58.


Cardiovascular safety and gastrointestinal tolerability of etoricoxib vs diclofenac in a randomized controlled clinical trial (The MEDAL study).

Combe B, Swergold G, McLay J, McCarthy T, Zerbini C, Emery P, Connors L, Kaur A, Curtis S, Laine L, Cannon CP.

Rheumatology (Oxford). 2009 Apr;48(4):425-32. doi: 10.1093/rheumatology/kep005. Epub 2009 Feb 17.

Items per page

Supplemental Content

Write to the Help Desk